Drug intelligence / Profile preview

ASCT-1003

Development stage: Preclinical
Lead developer: Alcamena Stem Cell Therapeutics
Modality: Stem Cell Therapies → Cell Therapies

Overview

ASCT-1003 is an investigational cell therapy developed by Alcamena Stem Cell Therapeutics. It is designed to function as an antagonist of the RE1-Silencing Transcription factor (REST), a protein that suppresses the expression of neuronal genes and is implicated in the progression of neurodegenerative diseases and various cancers. The therapy utilizes the β-TrCP (Beta-transducin repeat-containing protein) pathway to mediate its antagonistic effect on REST. ASCT-1003 is currently in the discovery and preclinical stages for indications including Alzheimer's disease, Parkinson's disease, dementia, colon cancer, and breast cancer.

Targets

BTRC (Beta-transducin repeat-containing protein)REST (Repressor element-1 silencing transcription factor)

Beyond the preview

Go deeper on ASCT-1003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASCT-1003.

Explore the full profile